In the News

June 26, 2017
Muscular Dystrophy News Today: Edasalonexent Could Reduce Functional Decline in Boys with DMD, MoveDMD Phase 2 Results Suggest

June 2, 2017
Muscular Dystrophy News Today: MoveDMD Study Continuing to Progress, Catabasis CEO Says in Interview

May 2, 2017
Scrip Intelligence: Catabasis Pursues Bifunctional Mutation-Agnostic Approach To DMD

April 26, 2017
BioWorld: In the clinic

February 3, 2017
Muscular Dystrophy News Today: Part B of MoveDMD Trial Shows Mixed Efficacy Results for CAT-1004 as Duchenne Treatment

January 9, 2017
Cystic Fibrosis News Today: Catabasis Aims for Phase 1 Trial of Cystic Fibrosis Therapy with Convincing Preclinical Data

September 29, 2016
BioCentury: Catabasis, Sarepta to Study DMD Combination

September 29, 2016
BioPharmaDIVE: Catabasis hopes to ride Sarepta approval wave

September 29, 2016
Boston Business Journal: Sarepta announces Duchenne research partnership with Cambridge's Catabasis

September 25, 2016
Scrip Intelligence: DMD Pipeline: After Sarepta's First-Ever Approval, Are Combinations Next?

April 19, 2016
Scrip Intelligence: Patient Registries Prove Value As Drug Development Tools

February 18, 2016
BioCentury Innovations: Crossing Paths - Linking inflammation and oxidation in ALS

February 5, 2016
Genetic Engineering & Biotechnology News: MDA Partners with Catabasis in Trial of DMD Candidate

January 25, 2016
Boston Business Journal: Duchenne drug by Cambridge's Catabasis looks safe in early trial

November 3, 2015
Boston Business Journal: In the footsteps of Sarepta: 7 other drugmakers working on Duchenne

June 25, 2015
FierceBiotech: Catabasis pulls off a $60M IPO as biotech's Wall Street window stays open

May 14, 2015
Xconomy: After Shift to Duchenne and Cholesterol Drugs, Catabasis Files For IPO